Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib plus pembrolizumab vs pembrolizumab in KRAS G12C-mutant NSCLC (CTR20240835)
CTR20240835Phase 3Active
- Sponsor
- Mirati Therapeutics
- Start
- Sep 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Started Sep 2024; status: active.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240835.